IL256827A - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Info

Publication number
IL256827A
IL256827A IL256827A IL25682718A IL256827A IL 256827 A IL256827 A IL 256827A IL 256827 A IL256827 A IL 256827A IL 25682718 A IL25682718 A IL 25682718A IL 256827 A IL256827 A IL 256827A
Authority
IL
Israel
Prior art keywords
interleukin
receptor
inflammatory diseases
peptide inhibitors
treat inflammatory
Prior art date
Application number
IL256827A
Other languages
Hebrew (he)
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/en
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of IL256827A publication Critical patent/IL256827A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL256827A 2015-07-15 2018-01-10 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL256827A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2015/040658 WO2016011208A1 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 US9624268B2 (en) 2014-07-17 2015-07-15 Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P 2015-12-08 2015-12-08
US201662281123P 2016-01-20 2016-01-20
PCT/US2016/042680 WO2017011820A2 (en) 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (1)

Publication Number Publication Date
IL256827A true IL256827A (en) 2018-03-29

Family

ID=57757647

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256827A IL256827A (en) 2015-07-15 2018-01-10 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (23)

Country Link
EP (1) EP3341011A4 (en)
JP (1) JP6858174B2 (en)
KR (1) KR102513978B1 (en)
CN (1) CN108348580B (en)
AU (1) AU2016293619B2 (en)
BR (1) BR112018000691A2 (en)
CA (1) CA2991984A1 (en)
CL (3) CL2018000128A1 (en)
CO (1) CO2018000349A2 (en)
CR (1) CR20180029A (en)
DO (1) DOP2018000010A (en)
EA (1) EA035733B9 (en)
EC (1) ECSP18002929A (en)
HK (2) HK1257747A1 (en)
IL (1) IL256827A (en)
MX (1) MX2018000542A (en)
NI (1) NI201800008A (en)
PE (1) PE20180571A1 (en)
PH (1) PH12018500086A1 (en)
SG (1) SG10201912066SA (en)
SV (1) SV2018005614A (en)
UA (1) UA123772C2 (en)
WO (1) WO2017011820A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03300B (en) 2012-06-13 2019-07-20 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
ES2657451T3 (en) 2013-04-19 2018-03-05 Incyte Holdings Corporation Bicyclic heterocyclics as FGFR inhibitors
DK3143037T3 (en) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc ALPHA4BETA7-INTEGRIN-THIOETHER-PEPTIDE ANTAGONISTS
RU2736637C9 (en) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases
JP2017535527A (en) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド Novel α4β7 peptide monomer and dimer antagonist
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
ES2751669T3 (en) 2015-02-20 2020-04-01 Incyte Corp Bicyclic heterocycles as FGFR inhibitors
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
WO2018136646A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
CA3073806A1 (en) 2017-09-11 2019-03-14 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
JP2021523118A (en) 2018-05-04 2021-09-02 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ FGFR inhibitor salt
CR20200590A (en) 2018-05-04 2021-04-26 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110015978B (en) * 2019-04-29 2021-03-19 康化（上海）新药研发有限公司 Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3997105A4 (en) * 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) * 2019-11-07 2021-05-12 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
JP2023505257A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Derivatives of FGFR inhibitors
JP2023505258A (en) 2019-12-04 2023-02-08 インサイト・コーポレイション Tricyclic heterocycles as FGFR inhibitors
CN118005737A (en) 2020-01-15 2024-05-10 詹森生物科技公司 Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases
CA3202226A1 (en) 2020-11-20 2022-05-27 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023288017A2 (en) * 2021-07-14 2023-01-19 Janssen Biotech, Inc. Bicyclic peptide inhibitors of interleukin-23 receptor
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) * 2022-03-09 2023-09-14 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) * 2022-03-17 2023-11-07 北京大学 Staple peptide, preparation method and pharmaceutical application thereof
WO2024003313A1 (en) 2022-06-30 2024-01-04 Sanofi New peptides as selective il-23 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
MX2009008241A (en) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
US20100190710A1 (en) * 2007-07-06 2010-07-29 Valorisation Hsj, Societe En Commandite Il-23 receptor antagonists and uses thereof
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US10416172B2 (en) * 2010-03-31 2019-09-17 Medical Diagnostic Laboratories, Llc Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) * 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
RU2736637C9 (en) * 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases

Also Published As

Publication number Publication date
CN108348580B (en) 2022-05-10
CL2018000128A1 (en) 2018-06-15
CR20180029A (en) 2018-06-05
PH12018500086A1 (en) 2018-07-30
KR102513978B1 (en) 2023-03-27
JP2018522008A (en) 2018-08-09
WO2017011820A2 (en) 2017-01-19
CL2021000343A1 (en) 2021-08-06
CN108348580A (en) 2018-07-31
AU2016293619B2 (en) 2021-02-25
EP3341011A4 (en) 2019-02-20
KR20180030663A (en) 2018-03-23
EA035733B1 (en) 2020-07-31
CL2018003322A1 (en) 2019-01-18
EA035733B9 (en) 2021-01-14
CA2991984A1 (en) 2017-01-19
ECSP18002929A (en) 2018-03-31
MX2018000542A (en) 2018-06-27
PE20180571A1 (en) 2018-04-04
DOP2018000010A (en) 2018-03-30
JP6858174B2 (en) 2021-04-14
SV2018005614A (en) 2018-05-22
UA123772C2 (en) 2021-06-02
WO2017011820A3 (en) 2017-02-23
HK1257747A1 (en) 2019-10-25
BR112018000691A2 (en) 2018-09-18
SG10201912066SA (en) 2020-02-27
CO2018000349A2 (en) 2018-07-10
EP3341011A2 (en) 2018-07-04
EA201890325A1 (en) 2018-06-29
NI201800008A (en) 2018-06-29
HK1259149A1 (en) 2019-11-29
AU2016293619A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
HK1259149A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL285614A (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3570864A4 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3820883A4 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL253796A0 (en) Therapeutically active compounds and their methods of use
HK1219657A1 (en) Use of agonists of formyl peptide receptor for treating ocular inflammatory diseases
IL249223A0 (en) Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
IL251246A0 (en) Therapeutically active compounds and their methods of use
ZA201700786B (en) Protein kinase c inhibitors and methods of their use
IL253118A0 (en) Methods of treating inflammatory diseases
HK1252037A1 (en) Methods of treating inflammatory diseases
HK1211471A1 (en) Treating th2-mediated diseases by inhibition of bromodomain- comprising proteins brd7 and brd9 brd7 brd9 th2
IL256515A (en) Therapeutic peptides and methods of use thereof
IL289628A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
PL3157531T3 (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
IL249098A0 (en) Methods and compositions for treating allergy and inflammatory diseases
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
DK3229827T3 (en) MODIFIED PEPTIDES AND ITS APPLICATION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
IL241934A (en) Inhibitory peptides for the treatment of inflammatory diseases
EP3139944A4 (en) Use of peptide for treating angiogenesis-related diseases
HUP1500192A2 (en) Use of mannooligosaccharides for treating human inflammatory bowel diseases
GB201418096D0 (en) Novel polymorph for use in treatment of inflammatory skin and pruritic disorders